公开(公告)号：US20190389926A1

公开(公告)日：2019-12-26

申请号：US16563987

申请日：2019-09-09

Applicant: UNIVERSITÄT BASEL

Inventor： Gennaro DE LIBERO ,  Marco LEPORE ,  Lucia MORI

IPC: C07K14/725 ,  C12N5/0783 ,  G01N1/30 ,  G01N33/569 ,  C12N5/09 ,  C12N15/85 ,  A61P35/00 ,  A61K35/17

Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells.The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.

公开(公告)号：US20230099822A1

公开(公告)日：2023-03-30

申请号：US17793419

申请日：2021-01-18

Applicant: UNIVERSITÄT BASEL

Inventor： Gennaro DE LIBERO ,  Lucia MORI ,  Alessandro VACCHINI ,  Andrew CHANCELLOR ,  Julian SPAGNUOLO ,  Qinmei YANG

IPC: G01N33/50 ,  G01N33/574 ,  C07D239/70

Abstract: The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a cell.
The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.

公开(公告)号：US20240002465A1

公开(公告)日：2024-01-04

申请号：US18353119

申请日：2023-07-17

Applicant: UNIVERSITÄT BASEL

Inventor： Gennaro DE LIBERO ,  Marco LEPORE ,  Lucia MORI

IPC: C07K14/725 ,  C12N15/86

CPC classification number: C07K14/7051 ,  C12N15/86

Abstract: Described herein is a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.

公开(公告)号：US20220339271A1

公开(公告)日：2022-10-27

申请号：US17275233

申请日：2019-09-11

Applicant: Universität Basel

Inventor： Gennaro DE LIBERO ,  Marco LEPORE ,  Lucia MORI

IPC: A61K39/00 ,  C07K14/725 ,  A61P35/00 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/86

Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells.
The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.